Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sara Parola
Observed name:
S. Parola
Institution:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Observed institutions:
Federico II University Hospital,
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale",
Istituti di Ricovero e Cura a Carattere Scientifico,
University of Naples Federico II
ORCID:
0000-0002-7786-0688
Observed ORCID:
0000-0002-7786-0688
OpenAlex ID:
A5044174065
BRAF Gene and Melanoma: Back to the Future
2021
·
Margaret Ottaviano
, Emilio Giunta
, et al.
·
International Journal of Molecular Sciences
·
130
PDF
Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
2023
·
Andrea D’Arienzo
, Annarita Verrazzo
, et al.
·
EClinicalMedicine
·
126
PDF
Epigenetic Regulation in Melanoma: Facts and Hopes
2021
·
Emilio Francesco Giunta
, Gianluca Arrichiello
, et al.
·
Cells
·
51
PDF
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer
2022
·
Roberto Buonaiuto
, Fabiana Napolitano
, et al.
·
Biomolecules
·
31
PDF
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study
2021
·
F. Schettini
, B. Conte
, et al.
·
ESMO Open
·
22
PDF
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?
2022
·
Giovanna Garufi
, Luisa Carbognin
, et al.
·
Cancer Treatment Reviews
·
21
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists
2020
·
Margaret Ottaviano
, Marcello Curvietto
, et al.
·
Journal for ImmunoTherapy of Cancer
·
20
PDF
The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something?
2021
·
Margaret Ottaviano
, Emilio Giunta
, et al.
·
International Journal of Molecular Sciences
·
13
PDF
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study
2024
·
Simone Scagnoli
, Simona Pisegna
, et al.
·
npj Breast Cancer
·
12
PARP inhibitors in testicular germ cell tumors: what we know and what we are looking for
2024
·
Sara Parola
, Christoph Oing
, et al.
·
Frontiers in Genetics
·
10
PDF
A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA
2021
·
Margaret Ottaviano
, Mario Giuliano
, et al.
·
Frontiers in Oncology
·
10
PDF
Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an overview of current applications, challenges, and emerging opportunities
2025
·
Sara Parola
, Ilaria Colombo
·
Exploration of Targeted Anti-tumor Therapy
·
8
PDF
Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report
2023
·
Roberta Caputo
, Martina Pagliuca
, et al.
·
Frontiers in Oncology
·
6
PDF
Long-term toxicity profile of trastuzumab emtansine (T-DM1): A multicenter real-life study.
2019
·
Giuseppe Buono
, Alessandra Fabi
, et al.
·
Journal of Clinical Oncology
·
6
Mediastinal soft tissue sarcoma: dark sides and future lights
2020
·
Giovannella Palmieri
, Marianna Tortora
, et al.
·
Mediastinum
·
5
Low-dose oral etoposide is an active option for patients with heavily pre-treated thymic epithelial tumors.
2020
·
Margaret Ottaviano
, Marianna Tortora
, et al.
·
Journal of Clinical Oncology
·
5
The long road after breast cancer: survivorship issues and long-term treatment effects in young women
2026
·
Martina Pagliuca
, Roberto Buonaiuto
, et al.
·
Frontiers in Oncology
·
1
PDF
Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study
2024
·
Simone Scagnoli
, Simona Pisegna
, et al.
·
npj Breast Cancer
·
1
105P CDK4/6 inhibitors in hormone receptor-positive, HER2-negative, locally advanced breast cancer (LABC): Biological and clinical activity, and post-surgical approaches
2022
·
S. Parola
, V. Di Lauro
, et al.
·
Annals of Oncology
·
1
Prognostic value of hormone receptor expression in patients with HR+/HER2− advanced BC treated with first-line ET+CDK4/6i: results from the multicentre observational, real-world PALMARES-2 study
2026
·
Francesca Ligorio
, Leonardo Provenzano
, et al.
·
EClinicalMedicine
AI-Enhanced PROMs and Drug-Drug Interaction Screening in Advanced Breast Cancer: Protocol of a Prospective Observational Pilot Study
2026
·
Ornella Tinelli
, Claudia Von Arx
, et al.
·
Epidemiology Biostatistics and Public Health
PDF
CDK4/6i in the Underrepresented Histological Subtypes of HR±/HER2- Metastatic Breast Cancer: A Real-World Cohort Study of Effectiveness and Safety
2026
·
Claudia von Arx
, Alessandra Calabrese
, et al.
·
Clinical Breast Cancer
568eP Early progression to CDK4/6 inhibitors plus endocrine therapy in HR+/HER2− metastatic breast cancer: A real-world analysis
2026
·
M. Tafuro
, M. Piezzo
, et al.
·
ESMO Open
457P Real-world outcomes and immunotherapy efficacy in patients with ER-low and triple-negative metastatic breast cancer: A GIM14 multicenter retrospective analysis
2026
·
T. Ruelle
, E. Blondeaux
, et al.
·
ESMO Open
PDF
557eP OVAL-T-Dxd: Real-world assessment of ovarian function suppression (OFS) during trastuzumab deruxtecan (T-Dxd) therapy in premenopausal, hormone-receptor–positive (HR+/HER2-Low) metastatic breast cancer (mBC)
2026
·
S. Parola
, O. Tinelli
, et al.
·
ESMO Open
PDF
Show more works
View as search
Works count:
31
Citation count:
479
H-index:
10
I10-index:
11
Year
Topic
Type